Should hyperlipidemia in children with the nephrotic syndrome be treated?

Pediatric Nephrology

Volumn 13, Issue 1, 1999, Pages 77-84

  Querfeld, Uwe ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Cardiovascular risk factors; Chronic renal failure; Hyperlipidemia; Nephrotic syndrome

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; STATINE DERIVATIVE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CATABOLISM; CHILD; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHRONIC KIDNEY FAILURE; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; LIVER; NEPHROTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CHILD; HUMANS; HYPERLIPIDEMIAS; NEPHROTIC SYNDROME;

EID: 0032966030     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670050568     Document Type: Review

References (83)

1. Anonymous (1986) Demography of dialysis and transplantation in Europe, 1984. Nephrol Dial Transplant 1:1-8
2. Braunwald E (1997) Shattuck lecture - cardiovascular medicine at the turn of the millenium: triumphs, concerns, and opportunities. N Engl J Med 337:1360-1369
3. Anonymous (1992) National Cholesterol Education Program (NCEP): highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89: 495-501
4. Anonymous (1992) National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89 [suppl]:525-584
5. Anonymous (1988) The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 9:571-600
6. Anonymous (1995) Nationale cardiovaskuläre Initiative: Erkennung und Behandlung von Fettstoffwechselstörungen. Dtsch Ärztebl 92:1-12
7. Baxter JH, Goodman HC, Havel RJ (1960) Serum lipid and lipoprotein alterations in nephrosis. J Clin Invest 39:455-465
8. Querfeld U, Gnasso A, Haberbosch W, Augustin J, Schärer K (1988) Lipoprotein profiles at different stages of the nephrotic syndrome. Eur J Pediatr 147:233-238
9. Querfeld U, Lang M, Friedrich JB, Kohl B, Fiehn W, Schärer K (1993) Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease. Pediatr Res 34:772-776
10. Gansevoort RT, Heeg JE, Dikkeschei FD, Zeeuw D de, Jong PE de, Dullaart RPF (1994) Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 9:244-250
11. Kronenberg F, Utermann G, Dieplinger H (1996) Lipoprotein(a) in renal disease. Am J Kidney Dis 27:1-25
12. Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Gröchenig E, Utermann G, Dieplinger H (1994) Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14:1405-1411
13. Cressman MD, Heyka RJ, Paganini EP, O'Neill J, Skibinski CI, Hoff HF (1992) Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482
14. Wheeler DC, Bernard DB (1994) Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 23:331-346
15. Marsh JB, Sparks CE (1979) Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis. J Clin Invest 64:1229-1237
16. Radding CM, Steinberg D (1960) Studies on the synthesis and secretion of serum lipoproteins by rat liver slices. J Clin Invest 39:1560-1569
17. Baxter JH, Goodman HC, Allen JC (1961) Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis. J Clin Invest 40:490-498
18. Kaysen GA, Gambertoglio J, Felts J, Hutchinson FN (1987) Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients. Kidney Int 31:1368-1376
19. Staprans I, Garon SJ, Hopper J, Felts JM (1981) Characterization of glycosaminoglycans in urine from patients with nephrotic syndrome and control subjects, and their effects on lipoprotein lipase. Biochim Biophys Acta 678:414-422
20. Chan MK, Persaud JW, Varghese Z, Moorhead J (1984) Post-heparin hepatic and lipoprotein lipase activities in nephrotic syndrome. Aust NZ J Med 14:841-847
21. Kashyap ML, DeMendozo SG, Campbell M, Shen CY, Lutmer RF, Glueck CJ (1978) Lipoprotein lipase activator deficiency in very low density lipoproteins in rat nephrotic syndrome. Experientia 34:1044-1045
22. Liang K. Vaziri ND (1997) Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 51:1761-1765
23. Berlyne GM, Mallick NP (1969) Ischaemic heart disease as a complication of nephrotic syndrome. Lancet II:399-400
24. Hopper J, Ryan P, Lee JC, Rosenman W (1970) Lipoid nephrosis in 31 adult patients. Medicine (Baltimore) 49:321-341
25. Alexander JH, Schapel GJ, Edwards KDG (1974) Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust 2: 207-208
26. Gilboa N (1976) Incidence of coronary heart disease associated with nephrotic syndrome. Med J Aust 1:207-208
27. Vosnides G, Cameron JS (1974) Hyperlipidemia in renal disease. Med J Aust 2:855
28. Wass V, Chilvers C, Jarrettt RJ, Cameron JS (1979) Does the nephrotic syndrome increase the risk of cardiovascular disease? Lancet II:664-667
29. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH (1993) The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642
30. Hopp L, Gilboa N, Kurland G, Weichler N, Orchard TJ (1994) Acute myocardial infarction in a young boy with nephrotic syndrome: a case report and review of the literature. Pediatr Nephrol 8:290-294
31. Kallen RJ, Brynes RK, Aronson AJ, Lichtig C, Spargo BH (1977) Premature atherosclerosis in a 5-year-old with corticoid-refractory nephrotic syndrome. Am J Dis Child 131: 976-980
32. Keane WF, Kasiske BL, O'Donnell P, Kim Y (1991) The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 17:38-42
33. Diamond JR, Karnovsky J (1988) Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 33:917-942
34. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron G, Larsson R, Weiss L, Wedel H, Alaupovic P (1997) Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal failure. Nephrol Dial Transplant 12:1908-1915
35. Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet II:1309-1311
36. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924
37. Berliner JA, Haberland ME (1993) The role of oxidized low-density lipoprotein in atherogenesis. Curr Opin Lipidol 4:373-381
38. Maggi E, Bellazzi R, Falaschi F, Franttoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G (1994) Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 45:876-883
39. Wheeler D, Chana RS (1993) Interactions between lipoproteins, glomerular cells and matrix. Miner Electrolyte Metab 19:149-164
40. Ong ACM, Moorhead JF (1994) Tubular lipidosis: epiphenomenon or pathogenetic lesion in human renal disease? Kidney Int 45:762
41. Magil AB, Frohlich JJ, Innis SM, Steinbrecher UP (1993) Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney Int 43:1243-1250
42. Coritsidis G, Rifice V, Gupta S, Rie J, Shan Z, Neugarten J, Schlondorff D (1991) Preferential uptake of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 39:866
43. Hessler JR, Morel DW, Lewis LJ, Chisolm GM (1983) Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 3:215-222
44. Fillit H, Elion E, Sullivan J, Sherman R, Zabriskie JB (1981) Thiobarbituric acid reactive material in uremic blood. Nephron 29:40-43
45. Maher ER, Wickens DB, Griffin JFA, Kyle P, Curtis JR, Dormandy TL (1987) Increased free-radical activity during haemodialysis. Nephrol Dial Transplant 2:169-171
46. Schettler V, Wieland E, Verwiebe R, Schuft-Werner P, Scheler F, Oellerich M (1994) Plasma lipids are not oxidized during hemodialysis. Nephron 67:42-47
47. D'Amico G, Gentile MG, Manna G, Fellin G, Ciceri R, Cofano F, Petrini C, Lavarda F, Perolini S, Porrini M (1992) Effect of vegetarian soy diet on hyperlipidemia in nephrotic syndrome. Lancet 339:1131-1134
48. Scharschmidt LA, Gibbons NB, McGarry L, Berger P, Axelrod M, Janis R, Ko YH (1987) Effects of dietary fish oil on renal insufficiency in rats with subtotal nephrectomy. Kidney Int 32:700-709
49. Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE (1994) A controlled trial offish oil in IgA nephropathy. N Engl J Med 331:1194-1199
50. De Caterina R, Caprioli R, Giannessi D, Sicari R, Galli C, Lazzerini G, Bernini W, Carr L, Rindi P (1993) N-fatty acids reduce proteinuria in patients with chronic glomerular disease. Kidney Int 44:843-850
51. Hau M-F, Smelt AHM, Bindels AJGH, Sijbrands EJG, Van der Laarse A, Onkenhout W, Van Duyvenvoorde W, Princen HMG (1996) Effects of fish oil on oxidation resistance of VLDL in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol 16:1197-1202
52. Valeri A, Gelfand J, Blum C, Appel GB (1986) Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am J Kidney Dis 8:388-396
53. Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA (1988) Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidemia of nephrotic syndrome. Lancet II:1335-1338
54. Groggel GC, Cheung AK, Ellis-Benigni K, Wilson DE (1989) Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int 36:266-271
55. Massy ZA, Ma JZ, Louis TA, Kasiske BL (1995) Lipid-lowering therapy in patients with renal disease. Kidney Int 48:198
56. Coleman JE, Watson AR (1996) Hyperlipidemia, diet and simvastatin in steroid resistant nephrotic syndrome of childhood. Pediatr Nephrol 10:171-174
57. Sanjad SA, Al-Abbad A, Al-Shorafa S (1997) Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 130:470-474
58. Querfeld U, Kohl B, Fiehn W, Minor T, Michalk D, Schärer K, Müller-Wiefel DE (1999) Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. Pediatr Nephrol 13:7-12
59. Thomas ME, Harris KPG, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, Williams JD, Walls J, Moorhead JF (1993) Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 44:1124-1129
60. Zilleruelo G, Hsia SL, Freundlich M, Gorman HM, Strauss J (1984) Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J Pediatr 104:61-64
61. Becker M, Staab D, Von Bergmann K (1993) Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol. J Pediatr 122:292-296
62. Becker M, Staab D, Von Bergmann K (1992) Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate. Pediatrics 89:138-142
63. Knipscheer HC, Boelen CCA, Kastelein JJP, Van Diermen DE, Groenemeijer BE, Van Den Ende A, Büller HR, Bakker HD (1996) Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 39:867-871
64. Lambert M, Lupien P, Gagne C, Levy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JTR, Wolfe BMJ, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J, and the Canadian Lovastatin in Children Study Group (1996) Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Pediatrics 97:619-628
65. Reijneveld JC, Koot RW, Bredman JJ, Joles JA, Bär PR (1996) Differential effects of 3-hydroxy-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res 39:1028-1035
66. Treasure CB, Klein L, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW (1995) Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332:481-487
67. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE (1994) Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24:1468-1474
68. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kajimoto Y, Morishima T, Kamada T (1994) Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging. Diabetes 43: 634-639
69. Rubba P, Mercuri M, Faccenda F, Iannuzzi A, Irace C, Strisciuglio P, Gnasso A, Tang R, Andria G, Bond MG, Mancini M (1994) Premature carotid atherosclerosis: does it occur in both familial hypercholesterolemia and homocystinuria? Ultrasound assessment of arterial intima-media thickness and blood flow velocity. Stroke 25:943-950
70. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE (1994) Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 93:50-55
71. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE (1993) Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 22:854-858
72. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115
73. Buntin CM, Silver FH (1990) Noninvasive assessment of mechanical properties of peripheral arteries. Ann Biomed Eng 18:549-566
74. Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, Bunce T, Dorado B, Deanfield JE, Rees L (1997) Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 52:468-472
75. Kwiterovich PO (1989) Beyond cholesterol. The Johns Hopkins complete guide for avoiding heart disease. The Johns Hopkins University Press, Baltimore
76. Hirano T, Mamo JCL, Nagano S, Sugisaki T (1991) The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. Nephron 58:95-100
77. Hirano T, Morohoshi T (1992) Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. Nephron 60:443-447
78. Modi KS, Schreiner GF, Purkerson ML, Klahr S (1992) Effects of probucol on renal function and structure in rats with subtotal kidney ablation. J Lab Clin Med 120:310-317
79. Hattori M, Ito K, Kawaguchi H, Yamaguchi Y (1994) Probucol reduces renal injury in the ExHC rat. Nephron 67:459-468
80. Naito H, Hirano T (1994) Probucol suppresses the development of chronic renal failure in Dahl salt-sensitive rats: an animal model of spontaneous focal and segmental glomerulosclerosis (letter). Nephron 67:125-126
81. Shimomura M (1995) The ameliorative effect of probucol on adriamycin (ADR) induced nephrotic rats. Nippon Jinzo Gakkai Shi 37:165-171
82. Yamasaki K, Yoshikawa Y (1995) Effect of a lipid-lowering agent or a high-cholesterol diet on focal glomerulosclerosis in hyperlipidemic rats. Lab Anim Sci 45:54-58
83. Magil A (1996) Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant. J Am Soc Nephrol 7:2340-2347